Indication
ANTICIPATED: As monotherapy for the treatment of adults and adolescents 12 years and older with advanced RET fusion-positive thyroid cancer (TC) who are radioactive iodine-refractory (if radioactive iodine is appropriate).
Medicine details
- Medicine name:
- selpercatinib (Retsevmo)
- SMC ID:
- SMC2733
- Pharmaceutical company
- Eli Lilly and Company Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Publication due date:
- TBC
- SMC meeting date:
- TBC
- Patient group submission deadline:
- TBC